Automatic delineation of cervical cancer target volumes in small samples based on multi-decoder and semi-supervised learning and clinical application.

Journal: Scientific reports
Published Date:

Abstract

Radiotherapy has been demonstrated to be one of the most significant treatments for cervical cancer, during which accurate and efficient delineation of target volumes is critical. To alleviate the data demand of deep learning and promote the establishment and promotion of auto-segmentation models in small and medium-sized oncology departments and single centres, we proposed an auto-segmentation algorithm to determine the cervical cancer target volume in small samples based on multi-decoder and semi-supervised learning (MDSSL), and we evaluated the accuracy via an independent test cohort. In this study, we retrospectively collected computed tomography (CT) datasets from 71 pelvic cervical cancer patients, and a 3:4 ratio was used for the training and testing sets. The clinical target volumes (CTVs) of the primary tumour area (CTV1) and pelvic lymph drainage area (CTV2) were delineated. For definitive radiotherapy (dRT), the primary gross target volume (GTVp) was simultaneously delineated. According to the data characteristics for small samples, the MDSSL network structure based on 3D U-Net was established to train the model by combining clinical anatomical information, which was compared with other segmentation methods, including supervised learning (SL) and transfer learning (TL). The dice similarity coefficient (DSC), 95% Hausdorff distance (HD95) and average surface distance (ASD) were used to evaluate the segmentation performance. The ability of the segmentation algorithm to improve the efficiency of online adaptive radiation therapy (ART) was assessed via geometric indicators and a subjective evaluation of radiation oncologists (ROs) in prospective clinical applications. Compared with the SL model and TL model, the proposed MDSSL model displayed the best DSC, HD95 and ASD overall, especially for the GTVp of dRT. We calculated the above geometric indicators in the range of the ground truth (head-foot direction). In the test set, the DSC, HD95 and ASD of the MDSSL model were 0.80/5.85 mm/0.95 mm for CTV1 of post-operative radiotherapy (pRT), 0.84/ 4.88 mm/0.73 mm for CTV2 of pRT, 0.84/6.58 mm/0.89 mm for GTVp of dRT, 0.85/5.36 mm/1.35 mm for CTV1 of dRT, and 0.84/4.09 mm/0.73 mm for CTV2 of dRT, respectively. In a prospective clinical study of online ART, the target volume modification time (MTime) was 3-5 min for dRT and 2-4 min for pRT, and the main duration of CTV1 modification was approximately 2 min. The introduction of the MDSSL method successfully improved the accuracy of auto-segmentation for the cervical cancer target volume in small samples, showed good consistency with RO delineation and satisfied clinical requirements. In this prospective online ART study, the application of the segmentation model was demonstrated to be useful for reducing the target volume delineation time and improving the efficiency of the online ART workflow, which can contribute to the development and promotion of cervical cancer online ART.

Authors

  • Haibo Peng
    Oncology Department, Clinical Medical College, The First Affiliated Hospital of Chengdu Medical College, Chengdu, 610500, China.
  • Tao Liu
    Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
  • Pengcheng Li
    Key Laboratory of Experimental Marine Biology, Institute of Oceanology, Chinese Academy of Sciences, Qingdao 266071, China. Electronic address: pcli@qdio.ac.cn.
  • Fang Yang
    College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, People's Republic of China.
  • Xing Luo
    College of Mechanical and Control Engineering, Guilin University of Technology, Guilin, Guangxi 541004, China.
  • Xiaoqing Sun
    Department of Radiology, China-Japan Union Hospital of Jilin University.
  • Dong Gao
    College of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
  • Fengyu Lin
    YIWEI Medical Technology Co., Ltd, Room 1001, MAI KE LONG Building, Nanshan, ShenZhen, 518000, China.
  • Lecheng Jia
    Shenzhen United Imaging Research Institute of Innovative Medical Equipment, Shenzhen, China. lecheng.jia@cri-united-imaging.com.
  • Ningyue Xu
    Oncology Department, Clinical Medical College, The First Affiliated Hospital of Chengdu Medical College, Chengdu, 610500, China.
  • Huigang Tan
    Oncology Department, Clinical Medical College, The First Affiliated Hospital of Chengdu Medical College, Chengdu, 610500, China.
  • Xi Wang
    School of Information, Central University of Finance and Economics, Beijing, China.
  • Tao Ren